RxDoctor Payments Data

Scot Holman, MD

Ophthalmology · Tavares, FLNPI 1467533505

Payments from drug & device makers

$20,023in general payments, 2019–2025

Across 237 payments — averaging $84.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$15K
  • Nova Eye, Inc.$1K
  • Ocular Therapeutix, Inc.$799
  • Sight Sciences, Inc.$759
  • AbbVie$737
  • Alcon$538
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$4,48222%
  • Speaking & faculty fees$8,02640%
  • Travel & lodging$6323%
  • Food & beverage$5,39127%
  • Gifts$450%
  • Entertainment$1,2976%
  • Other$1501%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,023 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$599,205
Medicare patients
1,175
Services billed
4,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine99$142,805
XiidraLifitegrast86$109,944
Cyclosporine39$25,656
LumiganBimatoprost32$23,005
Prednisolone Acetate309$10,129
Timolol Maleate97$4,848
Brimonidine Tartrate68$4,689
Latanoprost354$4,043
Dorzolamide-TimololDorzolamide/Timolol/Pf15$3,028
Loteprednol Etabonate19$2,671
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$2,652
Fluorometholone18$1,933
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat134$1,693
Acetazolamide20$670
ErythromycinErythromycin Base39$403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$737$165,810131 claims
Bausch & Lomb Americas Inc.Xiidra$39$109,94486 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$19$2,67119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Tavares

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →